Prot #KTE-C19-107: A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)

Project: Research project

Project Details

StatusFinished
Effective start/end date10/12/1810/12/23

Funding

  • DrugDev Inc. ((OE) Prot #KTE-C19-107 // (OE) Prot #KTE-C19-107)
  • Kite Pharma, Inc. ((OE) Prot #KTE-C19-107 // (OE) Prot #KTE-C19-107)